Selenoinsulin

Selenoinsulin (abbreviated to Se-Ins) is an experimental insulin analogue first described in 2017. It is a modified form of bovine pancreatic insulin in which the interchain disulfide bond between residues A7 and B7 is replaced with a diselenide bond formed by two selenocysteine residues. In laboratory studies, selenoinsulin retained biological activity comparable to that of bovine pancreatic insulin and showed greater resistance to degradation by the insulin-degrading enzyme (IDE).[1][2]

References

  1. ↑ Arai, Kenta; Takei, Toshiki; Okumura, Masaki; Watanabe, Satoshi; Amagai, Yuta; Asahina, Yuya; Moroder, Luis; Hojo, Hironobu; Inaba, Kenji; Iwaoka, Michio (2017-05-08). "Preparation of Selenoinsulin as a Long-Lasting Insulin Analogue". Angewandte Chemie International Edition. 56 (20): 5522–5526. doi:10.1002/anie.201701654. ISSN 1433-7851. PMID 28394477.
  2. ↑ Arai, Kenta; Okumura, Masaki; Lee, Young-Ho; Katayama, Hidekazu; Mizutani, Kenji; Lin, Yuxi; Park, Sam-Yong; Sawada, Kaichiro; Toyoda, Masao; Hojo, Hironobu; Inaba, Kenji; Iwaoka, Michio (2023-11-21). "Diselenide-bond replacement of the external disulfide bond of insulin increases its oligomerization leading to sustained activity". Communications Chemistry. 6 (1) 258. Bibcode:2023CmChe...6..258A. doi:10.1038/s42004-023-01056-4. ISSN 2399-3669. PMC 10663622. PMID 37989850.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.